The use of thiols by ribonucleotide reductase

Free Radical Biology and Medicine

Volumn 49, Issue 11, 2010, Pages 1617-1628

  Holmgren, Arne ^a   Sengupta, Rajib ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Disulfide; DNA synthesis; Enzyme mechanism; Free radicals; Glutaredoxin; Ribonucleotide reductase; Thiol; Thioredoxin; Thiyl radical

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CYSTEINE DERIVATIVE; DEOXYRIBONUCLEOTIDE; FREE RADICAL; RADICAL; RIBONUCLEOTIDE REDUCTASE; THIOL DERIVATIVE; THIOREDOXIN;

DNA REPAIR; DNA REPLICATION; DNA SYNTHESIS; ENZYME MECHANISM; NUCLEOTIDE METABOLISM; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN FAMILY; REVIEW;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; CATALYSIS; HUMANS; MODELS, BIOLOGICAL; RIBONUCLEOTIDE REDUCTASES; STRUCTURE-ACTIVITY RELATIONSHIP; SULFHYDRYL COMPOUNDS; SULFHYDRYL REAGENTS;

EID: 78049374613     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2010.09.005     Document Type: Review

References (112)

1. Le Moan N., Tacnet F., Toledano M.B. Protein-thiol oxidation, from single proteins to proteome-wide analyses. Methods Mol. Biol. 2008, 476:181-198.
2. Reichard P., Baldesten A., Rutberg L. Formation of deoxycytidine phosphates from cytidine phosphates in extracts from Escherichia coli. J. Biol. Chem. 1961, 236:1150-1157.
3. Holmgren A., Reichard P., Thelander L. Enzymatic synthesis of deoxyribonucleotides. 8. The effects of ATP and dATP in the CDP reductase system from E. coli. Proc. Natl Acad. Sci. USA 1965, 54:830-836.
4. Blakley R.L., Barker H.A. Cobamide stimulation of the reduction of ribotides to deoxyribotides in Lactobacillus leichmannii. Biochem. Biophys. Res. Commun. 1964, 16:391-397.
5. Stubbe J., Van Der Donk W.A. Protein radicals in enzyme catalysis. Chem. Rev. 1998, 98:705-762.
6. Lawrence C.C., Bennati M., Obias H.V., Bar G., Griffin R.G., Stubbe J. High-field EPR detection of a disulfide radical anion in the reduction of cytidine 5'-diphosphate by the E441Q R1 mutant of Escherichia coli ribonucleotide reductase. Proc. Natl Acad. Sci. USA 1999, 96:8979-8984.
7. Reichard P. From RNA to DNA, why so many ribonucleotide reductases?. Science 1993, 260:1773-1777.
8. Jordan A., Reichard P. Ribonucleotide reductases. Annu. Rev. Biochem. 1998, 67:71-98.
9. Nordlund P., Reichard P. Ribonucleotide reductases. Annu. Rev. Biochem. 2006, 75:681-706.
10. Kolberg M., Strand K.R., Graff P., Andersson K.K. Structure, function, and mechanism of ribonucleotide reductases. Biochim. Biophys. Acta 2004, 1699:1-34.
11. Eriksson M., Uhlin U., Ramaswamy S., Ekberg M., Regnström K., Sjöberg B.M., Eklund H. Binding of allosteric effectors to ribonucleotide reductase protein R1: reduction of active-site cysteines promotes substrate binding. Structure 1997, 5:1077-1092.
12. Håkansson P., Hofer A., Thelander L. Regulation of mammalian ribonucleotide reduction and dNTP pools after DNA damage and in resting cells. J. Biol. Chem. 2006, 281:7834-7841.
13. Tanaka H., Arakawa H., Yamaguchi T., Shiraishi K., Fukuda S., Matsui K., Takei Y., Nakamura Y. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 2000, 404:42-49.
14. Pontarin G., Fijolek A., Pizzo P., Ferraro P., Rampazzo C., Pozzan T., Thelander L., Reichard P.A., Bianchi V. Ribonucleotide reduction is a cytosolic process in mammalian cells independently of DNA damage. Proc. Natl Acad. Sci. USA 2008, 105:17801-17806.
15. Thelander L. Ribonucleotide reductase and mitochondrial DNA synthesis. Nat. Genet. 2007, 39:703-704.
16. Bourdon A., Minai L., Serre V., Jais J.P., Sarzi E., Aubert S., Chrétien D., de Lonlay P., Paquis-Flucklinger V., Arakawa H., Nakamura Y., Munnich A., Rötig A. Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion. Nat. Genet. 2007, 39:776-780.
17. Uhlin U., Eklund H. Structure of ribonucleotide reductase protein R1. Nature 1994, 370:533-539.
18. Eriksson M., Uhlin U., Ramaswamy S., Ekberg M., Regnström K., Sjöberg B.M., Eklund H. Binding of allosteric effectors to ribonucleotide reductase protein R1: reduction of active-site cysteines promotes substrate binding. Structure 1997, 5:1077-1092.
19. Nordlund P., Eklund H. Structure and function of the Escherichia coli ribonucleotide reductase protein R2. J. Mol. Biol. 1993, 232:123-164.
20. Smith P., Zhou B., Ho N., Yuan Y.C., Su L., Tsai S.C., Yen Y. 2.6 A X-ray crystal structure of human p53R2, a p53-inducible ribonucleotide reductase. Biochemistry 2009, 48:11134-11141.
21. Rofougaran R., Vodnala M., Hofer A. Enzymatically active mammalian ribonucleotide reductase exists primarily as an alpha6beta2 octamer. J. Biol. Chem. 2006, 281:27705-27711.
22. Rofougaran R., Crona M., Vodnala M., Sjöberg B.M., Hofer A. Oligomerization status directs overall activity regulation of the Escherichia coli class Ia ribonucleotide reductase. J. Biol. Chem. 2008, 283:35310-35318.
23. Sjöberg B.M., Sahlin M. Thiols in redox mechanism of ribonucleotide reductase. Methods Enzymol. 2002, 348:1-21.
24. Uhlin U., Eklund H. Structure of ribonucleotide reductase protein R1. Nature 1994, 370:533-539.
25. Xu H., Faber C., Uchiki T., Fairman J.W., Racca J., Dealwis C. Structures of eukaryotic ribonucleotide reductase I provide insights into dNTP regulation. Proc. Natl Acad. Sci. USA 2006, 103:4022-4027.
26. Eriksson M., Uhlin U., Ramaswamy S., Ekberg M., Regnström K., Sjöberg B.M., Eklund H. Binding of allosteric effectors to ribonucleotide reductase protein R1: reduction of active-site cysteines promotes substrate binding. Structure 1997, 5:1077-1092.
27. Pelmenschikov V., Cho K.B., Siegbahn P.E. Class I ribonucleotide reductase revisited: the effect of removing a proton on Glu441. J. Comput. Chem. 2004, 25:311-321.
28. Aberg A., Hahne S., Karlsson M., Larsson A., Ormö M., Ahgren A., Sjöberg B.M. Evidence for two different classes of redox-active cysteines in ribonucleotide reductase of Escherichia coli. J. Biol. Chem. 1989, 264:12249-12252.
29. Mao S.S., Holler T.P., Yu G.X., Bollinger J.M., Booker S., Johnston M.I., Stubbe J. A model for the role of multiple cysteine residues involved in ribonucleotide reduction: amazing and still confusing. Biochemistry 1992, 31:9733-9743.
30. Lin A.N., Ashley G.W., Stubbe J. Location of the redox-active thiols of ribonucleotide reductase: sequence similarity between the Escherichia coli and Lactobacillus leichmannii enzymes. Biochemistry 1987, 26:6905-6909.
31. Zhang Z., Yang K., Chen C.C., Feser J., Huang M. Role of the C terminus of the ribonucleotide reductase large subunit in enzyme regeneration and its inhibition by Sml1. Proc. Natl Acad. Sci. USA 2007, 104:2217-2222.
32. Lawrence C.C., Stubbe J. The function of adenosylcobalamin in the mechanism of ribonucleoside triphosphate reductase from Lactobacillus leichmannii. Curr. Opin. Chem. Biol. 1998, 2:650-655.
33. Booker S., Licht S., Broderick J., Stubbe J. Coenzyme B12-dependent ribonucleotide reductase: evidence for the participation of five cysteine residues in ribonucleotide reduction. Biochemistry 1994, 33:12676-12685.
34. Sun X., Ollagnier S., Schmidt P.P., Atta M., Mulliez E., Lepape L., Eliasson R., Gräslund A., Fontecave M., Reichard P., Sjöberg B.M. The free radical of the anaerobic ribonucleotide reductase from Escherichia coli is at glycine 681. J. Biol. Chem. 1996, 271:6827-6831.
35. Bianchi V., Eliasson R., Fontecave M., Mulliez E., Hoover D.M., Matthews R.G., Reichard P. Flavodoxin is required for the activation of the anaerobic ribonucleotide reductase. Biochem. Biophys. Res. Commun. 1993, 197:792-797.
36. + reductase: activation of E. coli anaerobic ribonucleotide reduction, cloning of the gene (fpr), and overexpression of the protein. J. Bacteriol. 1993, 175:1590-1595.
37. Mulliez E., Padovani D., Atta M., Alcouffe C., Fontecave M. Activation of class III ribonucleotide reductase by flavodoxin: a protein radical-driven electron transfer to the iron-sulfur center. Biochemistry 2001, 40:3730-3736.
38. Logan D.T., Andersson J., Sjöberg B.M., Nordlund P. A glycyl radical site in the crystal structure of a class III ribonucleotide reductase. Science 1999, 283:1499-1504.
39. Holmgren A. Thioredoxin and glutaredoxin systems. J. Biol. Chem. 1989, 264:13963-13966.
40. Mulliez E., Ollagnier-de Choudens S., Meier C., Cremonini M., Luchinat C., Trautwein A.X., Fontecave M. Iron-sulfur interconversions in the anaerobic ribonucleotide reductase from Escherichia coli. J. Biol. Inorg. Chem. 1999, 4:614-620.
41. Tamarit J., Mulliez E., Meier C., Trautwein A., Fontecave M. The anaerobic ribonucleotide reductase from Escherichia coli: the small protein is an activating enzyme containing a [4Fe-4S](2+) center. J. Biol. Chem. 1999, 274:31291-31296.
42. Ollagnier S., Mulliez E., Schmidt P.P., Eliasson R., Gaillard J., Deronzier C., Bergman T., Gräslund A., Reichard P., Fontecave M. Activation of the anaerobic ribonucleotide reductase from Escherichia coli: the essential role of the iron-sulfur center for S-adenosylmethionine reduction. J. Biol. Chem. 1997, 272:24216-24223.
43. Tamarit J., Gerez C., Meier C., Mulliez E., Trautwein A., Fontecave M. The activating component of the anaerobic ribonucleotide reductase from Escherichia coli: an iron-sulfur center with only three cysteines. J. Biol. Chem. 2000, 275:15669-15675.
44. Thelander L., Reichard P. Reduction of ribonucleotides. Annu. Rev. Biochem. 1979, 48:133-158.
45. Laurent T.C., Moore E.C., Rreichard P. Enzymatic synthesis of deoxyribonucleotides. IV. Isolation and characterization of thioredoxin, the hydrogen donor from Escherichia coli b. J. Biol. Chem. 1964, 239:3436-3444.
46. Holmgren A. Hydrogen donor system for Escherichia coli ribonucleoside-diphosphate reductase dependent upon glutathione. Proc. Natl Acad. Sci. USA 1976, 73:2275-2279.
47. Lillig C.H., Berndt C., Holmgren A. Glutaredoxin systems. Biochim. Biophys. Acta 2008, 1780:1304-1317.
48. Lillig C.H., Holmgren A. Thioredoxin and related molecules-from biology to health and disease. Antioxid. Redox Signaling 2007, 9:25-47.
49. Gallardo-Madueno R., Leal J.F., Dorado G., Holmgren A., Lopez-Barea J., Pueyo C. In vivo transcription of nrdAB operon and of grxA and fpg genes is triggered in Escherichia coli lacking both thioredoxin and glutaredoxin 1 or thioredoxin and glutathione, respectively. J. Biol. Chem. 1998, 273:18382-18388.
50. Prieto-Alamo M.J., Jurado J., Gallardo-Madueno R., Monje-Casas F., Holmgren A., Pueyo C. Transcriptional regulation of glutaredoxin and thioredoxin pathways and related enzymes in response to oxidative stress. J. Biol. Chem. 2000, 275:13398-13405.
51. Gon S., Faulkner M.J., Beckwith J. In vivo requirement for glutaredoxins and thioredoxins in the reduction of the ribonucleotide reductases of Escherichia coli. Antioxid. Redox Signaling 2006, 8:735-742.
52. Avval F.Z., Holmgren A. Molecular mechanisms of thioredoxin and glutaredoxin as hydrogen donors for mammalian S phase ribonucleotide reductase. J. Biol. Chem. 2009, 284:8233-8240.
53. Bushweller J.H., Billeter M., Holmgren A., Wüthrich K. The nuclear magnetic resonance solution structure of the mixed disulfide between Escherichia coli glutaredoxin(C14S) and glutathione. J. Mol. Biol. 1994, 235:1585-1597.
54. Aberg A., Hahne S., Karlsson M., Larsson A., Ormö M., Ahgren A., Sjöberg B.M. Evidence for two different classes of redox-active cysteines in ribonucleotide reductase of Escherichia coli. J. Biol. Chem. 1989, 264:12249-12252.
55. Lin A.N., Ashley G.W., Stubbe J. Location of the redox-active thiols of ribonucleotide reductase: sequence similarity between the Escherichia coli and Lactobacillus leichmannii enzymes. Biochemistry 1987, 26:6905-6909.
56. Meister A. Glutathione metabolism and its selective modification. J. Biol. Chem. 1988, 263:17205-17208.
57. Yoo M.H., Xu X.M., Carlson B.A., Patterson A.D., Gladyshev V.N., Hatfield D.L. Targeting thioredoxin reductase 1 reduction in cancer cells inhibits self-sufficient growth and DNA replication. PLoS ONE 2007, 2:e1112.
58. Rollins M.F., van der Heide D.M., Weisend C.M., Kundert J.A., Comstock K.M., Suvorova E.S., Capecchi M.R., Merrill G.F., Schmidt E.E. Hepatocytes lacking thioredoxin reductase 1 have normal replicative potential during development and regeneration. J. Cell Sci. 2010, 123:2402-2412.
59. Suthanthiran M., Anderson M.E., Sharma V.K., Meister A. Glutathione regulates activation-dependent DNA synthesis in highly purified normal human T lymphocytes stimulated via the CD2 and CD3 antigens. Proc. Natl Acad. Sci. USA 1990, 87:3343-3347.
60. Dethlefsen L.A., Lehman C.M., Biaglow J.E., Peck V.M. Toxic effects of acute glutathione depletion by buthionine sulfoximine and dimethylfumarate on murine mammary carcinoma cells. Radiat. Res. 1988, 114:215-224.
61. Markovic J., Borrás C., Ortega A., Sastre J., Viña J., Pallardó F.V. Glutathione is recruited into the nucleus in early phases of cell proliferation. J. Biol. Chem. 2007, 282:20416-20424.
62. Markovic J., Mora N.J., Broseta A.M., Gimeno A., de-la-Concepción N., Viña J., Pallardó F.V. The depletion of nuclear glutathione impairs cell proliferation in 3T3 fibroblasts. PLoS ONE 2009, 4:e6413.
63. Rojas E., Valverde M., Kala S.V., Kala G., Lieberman M.W. Accumulation of DNA damage in the organs of mice deficient in gamma-glutamyltranspeptidase. Mutat. Res. 2000, 447:305-316.
64. Andersson J., Westman M., Sahlin M., Sjoberg B.M. Cysteines involved in radical generation and catalysis of class III anaerobic ribonucleotide reductase: a protein engineering study of bacteriophage T4 NrdD. J. Biol. Chem. 2000, 275:19449-19455.
65. Padovani D., Mulliez E., Fontecave M. Activation of class III ribonucleotide reductase by thioredoxin. J. Biol. Chem. 2001, 276:9587-9589.
66. Logan D.T., Mulliez E., Larsson K.M., Bodevin S., Atta M., Garnaud P.E., Sjoberg B.M., Fontecave M. A metal-binding site in the catalytic subunit of anaerobic ribonucleotide reductase. Proc. Natl Acad. Sci. USA 2003, 100:3826-3831.
67. Luttringer F., Mulliez E., Dublet B., Lemaire D., Fontecave M. The Zn center of the anaerobic ribonucleotide reductase from E. coli. J. Biol. Inorg. Chem. 2009, 14:923-933.
68. Yim C.Y., Bastian N.R., Smith J.C., Hibbs J.B., Samlowski W.E. Macrophage nitric oxide synthesis delays progression of ultraviolet light-induced murine skin cancers. Cancer Res. 1993, 53:5507-5511.
69. Lepoivre M., Flaman J.M., Bobé P., Lemaire G., Henry Y. Quenching of the tyrosyl free radical of ribonucleotide reductase by nitric oxide: relationship to cytostasis induced in tumor cells by cytotoxic macrophages. J. Biol. Chem. 1994, 269:21891-21897.
70. Stuehr D.J., Nathan C.F. Nitric oxide: a macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J. Exp. Med. 1989, 169:1543-1555.
71. Nathan C.F., Hibbs J.B. Role of nitric oxide synthesis in macrophage antimicrobial activity. Curr. Opin. Immunol. 1991, 3:65-70.
72. Kwon N.S., Stuehr D.J., Nathan C.F. Inhibition of tumor cell ribonucleotide reductase by macrophage-derived nitric oxide. J. Exp. Med. 1991, 174:761-767.
73. Moncada S., Palmer R.M., Higgs E.A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 1991, 43:109-142.
74. Seki J., Nishio M., Kato Y., Motoyama Y., Yoshida K. FK409, a new nitric-oxide donor, suppresses smooth muscle proliferation in the rat model of balloon angioplasty. Atherosclerosis 1995, 117:97-106.
75. Von der Leyen H.E., Gibbons G.H., Morishita R., Lewis N.P., Zhang L., Nakajima M., Kaneda Y., Cooke J.P., Dzau V.J. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc. Natl Acad. Sci. USA 1995, 92:1137-1141.
76. Bundy R., Marczin N., Chester A.H., Yacoub M. Differential regulation of DNA synthesis by nitric oxide and hydroxyurea in vascular smooth muscle cells. Am. J. Physiol. 1999, 277:H1799-1807.
77. Lepoivre M., Fieschi F., Coves J., Thelander L., Fontecave M. Inactivation of ribonucleotide reductase by nitric oxide. Biochem. Biophys. Res. Commun. 1991, 179:442-448.
78. Lepoivre M., Flaman J.M., Henry Y. Early loss of the tyrosyl radical in ribonucleotide reductase of adenocarcinoma cells producing nitric oxide. J. Biol. Chem. 1992, 267:22994-23000.
79. Roy B., Lepoivre M., Henry Y., Fontecave M. Inhibition of ribonucleotide reductase by nitric oxide derived from thionitrites: reversible modifications of both subunits. Biochemistry 1995, 34:5411-5418.
80. Chabes A., Domkin V., Thelander L. Yeast Sml1, a protein inhibitor of ribonucleotide reductase. J. Biol. Chem. 1999, 274:36679-36683.
81. Ingemarson R., Thelander L. A kinetic study on the influence of nucleoside triphosphate effectors on subunit interaction in mouse ribonucleotide reductase. Biochemistry 1996, 35:8603-8609.
82. Ortigosa A.D., Hristova D., Perlstein D.L., Zhang Z., Huang M., Stubbe J. Determination of the in vivo stoichiometry of tyrosyl radical per betabeta? in Saccharomyces cerevisiae ribonucleotide reductase. Biochemistry 2006, 45:12282-12294.
83. Zhao X., Georgieva B., Chabes A., Domkin V., Ippel J.H., Schleucher J., Wijmenga S., Thelander L., Rothstein R. Mutational and structural analyses of the ribonucleotide reductase inhibitor Sml1 define its Rnr1 interaction domain whose inactivation allows suppression of mec1 and rad53 lethality. Mol. Cell. Biol. 2000, 20:9076-9083.
84. Håkansson P., Dahl L., Chilkova O., Domkin V., Thelander L. The Schizosaccharomyces pombe replication inhibitor Spd1 regulates ribonucleotide reductase activity and dNTPs by binding to the large Cdc22 subunit. J. Biol. Chem. 2006, 281:1778-1783.
85. Moore E.C., Sartorelli A.C. Inhibition of ribonucleotide reductase by alpha-(N)-heterocyclic carboxaldehyde thiosemicarbazones. Pharmacol. Ther. 1984, 24:439-447.
86. Nocentini G., Federici F., Grifantini M., Barzi A. Copper complex of a new ribonucleotide reductase inhibitor characterized by antitumoral properties. Pharmacol. Res. 1992, 25:312-313.
87. Antholine W.E., Kalyanaraman B., Petering D.H. ESR of copper and iron complexes with antitumor and cytotoxic properties. Environ. Health Perspect. 1985, 64:19-35.
88. Tamasi G., Chiasserini L., Savini L., Sega A., Cini R. Structural study of ribonucleotide reductase inhibitor hydrazones: synthesis and X-ray diffraction analysis of a copper(II)-benzoylpyridine-2-quinolinyl hydrazone complex. J. Inorg. Biochem. 2005, 99:1347-1359.
89. Schallreuter K.U., Wood J.M. New aspects in the pathophysiology of cutaneous melanoma: a review of the role of thioproteins and the effect of nitrosoureas. Melanoma Res. 1991, 1:159-167.
90. Hurta R.A., Wright J.A. Alterations in the activity and regulation of mammalian ribonucleotide reductase by chlorambucil, a DNA damaging agent. J. Biol. Chem. 1992, 267:7066-7071.
91. Piulats J.M., Jiménez L., García del Muro X., Villanueva A., Viñals F., Germà-Lluch J.R. Molecular mechanisms behind the resistance of cisplatin in germ cell tumours. Clin. Transl. Oncol. 2009, 11:780-786.
92. Smith S.L., Douglas K.T. Stereoselective, strong inhibition of ribonucleotide reductase from E. coli by cisplatin. Biochem. Biophys. Res. Commun. 1989, 162:715-723.
93. Chiu C.S., Chan A.K., Wright J.A. Inhibition of mammalian ribonucleotide reductase by cis-diamminedichloroplatinum(II). Biochem. Cell Biol. 1992, 70:1332-1338.
94. Larsen I.K., Cornett C., Karlsson M., Sahlin M., Sjöberg B.M. Caracemide, a site-specific irreversible inhibitor of protein R1 of Escherichia coli ribonucleotide reductase. J. Biol. Chem. 1992, 267:12627-12631.
95. Satyamoorthy K., Chitnis M.P., Advani S.H. In vitro cytotoxicity of caracemide alone and in combination with hydroxyurea or iron-chelating agents in human chronic myeloid leukemia cells and murine tumors. Neoplasma 1988, 35:27-35.
96. Newman R.A., Farquhar D., Lu K., Meyn R., Moore E.C., Massia S., Korp J.D., Wright J.A., McKinney M. Biochemical pharmacology of N-acetyl-N-(methylcarbamoyloxy)-N'-methylurea (caracemide; NSC-253272). Biochem. Pharmacol. 1986, 35:2781-2787.
97. Buccafusco J.J., Smith M.D. In vivo and in vitro cholinesterase inhibitor property of the antitumor agent caracemide. Res. Commun. Chem. Pathol. Pharmacol. 1990, 67:219-227.
98. Pazdur R., Chabot G.G., Baker L.H. Phase I study and pharmacokinetics of caracemide (NSC-253272) administered as a short infusion. Invest. New Drugs 1987, 5:365-371.
99. Raber M.N., Adams F., Kavanagh J., Legha S., Dimery I., Krakoff I. Phase I trial of caracemide using bolus and infusion schedules. Cancer Treat. Rep. 1987, 71:349-352.
100. Belani C.P., Eisenberger M., Van Echo D., Hiponia D., Aisner J. Phase II study of caracemide in advanced or recurrent non-small cell lung cancer. Cancer Treat. Rep. 1987, 71:1099-1100.
101. Lad T., Schor J., Mullane M., Carroll R., Chernicoff D., Blough R., Weidner L. Phase II trial of caracemide (NSC 253272) in advanced unresectable non-small cell bronchogenic carcinoma: an Illinois Cancer Council study. Invest. New Drugs 1992, 10:27-28.
102. Witte R.S., Lipsitz S., Goodman T.L., Asbury R.F., Wilding G., Strnad C.M., Smith T.J., Haller D.G. A phase II trial of homoharringtonine and caracemide in the treatment of patients with advanced large bowel cancer. Invest. New Drugs 1999, 17:173-177.
103. Witte R.S., Hsieh P., Elson P., Oken M.M., Trump D.L. A phase II trial of amonafide, caracemide, and homoharringtonine in the treatment of patients with advanced renal cell cancer. Invest. New Drugs 1996, 14:409-413.
104. Nocentini G. Ribonucleotide reductase inhibitors: new strategies for cancer chemotherapy. Crit. Rev. Oncol. Hematol. 1996, 22:89-126.
105. Shao J., Zhou B., Chu B., Yen Y. Ribonucleotide reductase inhibitors and future drug design. Curr. Cancer Drug Targets 2006, 6:409-431.
106. Patwari P., Higgins L.J., Chutkow W.A., Yoshioka J., Lee R.T. The interaction of thioredoxin with Txnip: evidence for formation of a mixed disulfide by disulfide exchange. J. Biol. Chem. 2006, 281:21884-21891.
107. Chutkow W.A., Patwari P., Yoshioka J., Lee R.T. Thioredoxin-interacting protein (Txnip) is a critical regulator of hepatic glucose production. J. Biol. Chem. 2008, 283:2397-2406.
108. Kim K.Y., Shin S.M., Kim J.K., Paik S.G., Yang Y., Choi I. Heat shock factor regulates VDUP1 gene expression. Biochem. Biophys. Res. Commun. 2004, 315:369-375.
109. Schulze P.C., Yoshioka J., Takahashi T., He Z., King G.L., Lee R.T. Hyperglycemia promotes oxidative stress through inhibition of thioredoxin function by thioredoxin-interacting protein. J. Biol. Chem. 2004, 279:30369-30374.
110. Watanabe R., Nakamura H., Masutani H., Yodoi J. Anti-oxidative, anti-cancer and anti-inflammatory actions by thioredoxin 1 and thioredoxin-binding protein-2. Pharmacol. Ther. 2010, 127:261-270.
111. Yoshihara E., Chen Z., Matsuo Y., Masutani H., Yodoi J. Thiol redox transitions by thioredoxin and thioredoxin-binding protein-2 in cell signaling. Methods Enzymol. 2010, 474:67-82.
112. Chen J., Fontes G., Saxena G., Poitout V., Shalev A. Lack of TXNIP protects against mitochondria-mediated apoptosis but not against fatty acid-induced ER stress-mediated beta-cell death. Diabetes 2010, 59:440-447.